Background {#s1}
==========

Although drug-induced liver injury (DILI) is a rare adverse drug event, it is often life-threatening because of the risk of developing acute liver failure. The mechanisms underlying DILI risk are not well understood and hence, the search for biomarkers of DILI risk is a major research field that aims to identify markers that could be used as both proof of the mechanisms involved and of the risk factors that can be used for DILI prediction, as has already been done with many pharmacogenomics biomarkers (Lucena et al., [@B13], [@B14]; Agúndez, [@B1]; Agundez et al., [@B5], [@B4]; Andrade et al., [@B6]; Robles-Diaz et al., [@B16]; Nicoletti et al., [@B15]). There are presently several independent hypotheses to explain idiosyncratic DILI, but none of these is able to explain all the circumstances in which DILI occurs.

Some genetic biomarkers for DILI either mechanistically-based using a case-control strategy or with a GWAs/exome sequencing approaches have been identified \[for a review, see (Robles-Diaz et al., [@B16])\]. However, the involvement of genetic changes in DILI risk (for instance HLA risk alleles) has been documented for only a few drugs (Kaliyaperumal et al., [@B9]). On the other hand, case-control genotyping studies, GWAS and exome sequencing have important limitations because only some SNPs are tested, and most of the target sequence is not checked. To overcome this problem, deep sequencing comprising whole genes is necessary.

In this study, we analyzed the potential effect of mutations in cyclooxygenase genes (*PTGS1* and *PTGS2*) on DILI risk related to NSAIDs. From a mechanistic point of view, such a risk could be related to genetic alteration in the arachidonic acid pathways, which are closely related to inflammation. On the other hand, adverse drug events for drugs acting on the COX enzymes (that is, COX inhibitors) may be more likely if COX activity is altered because of genetic variations. For this reason, we analyzed patients who developed DILI after the administration of COX-inhibitors and healthy individuals who tolerated COX-inhibitors.

Case Presentation {#s2}
=================

Thirteen patients (8 women and 5 men) who experienced DILI caused by COX inhibitors and 100 individuals who tolerated COX-inhibitors at standard doses were included in this study. The culprit drug for DILI and clinical details of patients are shown in [Table 1](#T1){ref-type="table"}. Gender-matched control individuals who tolerated COX-inhibitors (62 women and 38 men) individuals were recruited among staff and medical students of the Hospitals and the Universities participating in this study. Individuals which were considered as healthy after medical examination, to exclude pre-existing disorders and history of adverse events after the use of COX-inhibitors, were asked to participate and over 95% of these agreed to do so. We selected consecutive control subjects matched with patients for drug exposure: Fifty control subjects who have received ibuprofen within the previous month to sample collection, 20 who received diclofenac, 10 indomethacin, 10 naproxen, and 10 rofecoxib. These frequencies match with the frequencies for the DILI patients, except that no control subject received nimesulide since this drug was discontinued from the Spanish market due to liver safety. Both patients and controls were Caucasian Spanish individuals. Written informed consent for participation in this case report was obtained from all participants. The protocol for this study was in accordance with the Declaration of Helsinki and its subsequent revisions and was approved by the respective Ethics Committees of the participating Hospitals.

###### 

Demographic and clinical characteristics of 13 patients with NSAIDs-induced idiosyncratic liver injury.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **N^**°**^**   **Culprit drug**   **Age/Sex**   **Indication**         **Daily dose (mg)**   **Duration treatment (days)**   **Time to onset (days)**   **Associated medications**     **Clinical presentation**   **Type of liver injury**   **TB (xULN)**   **ALT (xULN)**   **ALP (xULN)**   **Severity index**   **Outcome**         **CIOMS score**
  -------------- ------------------ ------------- ---------------------- --------------------- ------------------------------- -------------------------- ------------------------------ --------------------------- -------------------------- --------------- ---------------- ---------------- -------------------- ------------------- -----------------
  1              Diclofenac         76/F          Lumbar Pain            50                    93                              30                         Levothyroxine\                 Jaundice\                   HC                         2.9             24               2.6              Moderate             Resolution\         Highly\
                                                                                                                                                          Metamizole                     ASMA 1/80                                                                                                                     221 days            probable

  2              Nimesulide         62/F          Osteoarthritis         200                   30                              30                         None                           Jaundice\                   HC                         24              98               2.5              Moderate             Resolution\         Probable
                                                                                                                                                                                         Eosinophilia                                                                                                                  90 days             

  3              Nimesulide         61/F          Osteoarthritis         200                   62                              62                         Fosinopril\                    Jaundice                    HC                         15              30               1.7              Moderate,\           Resolution\         Highly\
                                                                                                                                                          Torasemide                                                                                                                              hospitalized         126 days            probable

  4              Indometacin        54/F          Osteoarthritis         100                   11                              8                          Tramadol\                      Elevated liver enzymes      Mix                        1               16               3.6              Mild                 Resolution\         Highly\
                                                                                                                                                          Tetrazepam\                                                                                                                                                  44 days             probable
                                                                                                                                                          Dexamethasone                                                                                                                                                                    

  5              Ibuprofen          64/F          Pain                   600                   17                              10                         Enalapril\                     Jaundice\                   Mix                        9               5.9              1.7              Moderate,\           Resolution\         Highly\
                                                                                                                                                          Insulin                        ASMA 1/40                                                                                                hospitalized         180 days            probable

  6              Naproxen           65/M          Pain                   1,000                 44                              48                         Tetrazepam\                    Jaundice                    Mix                        4.5             9.7              3.4              Moderate,\           Lost of follow-up   Highly\
                                                                                                                                                          Ranitidine\                                                                                                                             hospitalized                             probable
                                                                                                                                                          Heparin\                                                                                                                                                                         
                                                                                                                                                          Bisoprolol\                                                                                                                                                                      
                                                                                                                                                          Metamizole                                                                                                                                                                       

  7              Ibuprofen          18/M          Pain                   600                   1                               2                          None                           Jaundice\                   Mix                        7.9             5.5              2.6              Moderate,\           Lost of follow-up   Highly\
                                                                                                                                                                                         Lymphopenia                                                                                              hospitalized                             probable

  8              Rofecoxib          82/M          Osteoarthritis         12.5                  60                              59                         Nimodipine\                    Lymphopenia                 Chol                       2.6             4.9              4.4              Moderate             Resolution\         Highly\
                                                                                                                                                          Omeprazole\                                                                                                                                                  94 days             probable
                                                                                                                                                          Paracetamol\                                                                                                                                                                     
                                                                                                                                                          Troxerutin\                                                                                                                                                                      
                                                                                                                                                          Insulin\                                                                                                                                                                         
                                                                                                                                                          Vitamins\                                                                                                                                                                        
                                                                                                                                                          Folic Acid                                                                                                                                                                       

  9              Ibuprofen          57/M          Pain                   1,200                 31                              50                         Glibenclamide                  Elevated liver enzymes      HC                         1               24               0.9              Mild                 Lost of follow-up   Highly\
                                                                                                                                                                                                                                                                                                                                           probable

  10             Nimesulide         59/F          Osteoarthritis         200                   25                              466                        Atenolol\                      Eosinophilia                Chol                       1.2             1.2              5                Moderate,\           Resolution\         Highly\
                                                                                                                                                          Captopril\                                                                                                                              hospitalized         284 days            probable
                                                                                                                                                          Hydrochlorothiazide Insulin\                                                                                                                                                     
                                                                                                                                                          Metformin                                                                                                                                                                        

  11             Ibuprofen          43/M          Pain                   1,200                 8                               8                          Metronidazole                  Jaundice                    HC                         1.9             8.2              1.3              Mild,\               Resolution\         Probable
                                                                                                                                                                                                                                                                                                  hospitalized         308                 

  12             Diclofenac         80/F          Pain                   75                    171                             171                        Telmisartan\                   Jaundice                    HC                         4.9             38               1.9              Moderate,\           Resolution\         Highly\
                                                                                                                                                          Allopurinol\                                                                                                                            hospitalized         348                 probable
                                                                                                                                                          Glibenclamide Ebastine\                                                                                                                                                          
                                                                                                                                                          Troxerutin                                                                                                                                                                       

  13             Ibuprofen          41/F          Rheumatoid arthritis   600                   3                               7                          Diclofenac\                    Elevated liver enzymes      HC                         1.6             14               1.8              Mild                 Resolution 31       Probable
                                                                                                                                                          Paracetamol\                                                                                                                                                                     
                                                                                                                                                          Diazepam\                                                                                                                                                                        
                                                                                                                                                          Fluoxetine                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*F, Female; M, Male; ASMA, anti-smooth muscle autoantibody; HC, Hepatocellular, Mix, mixed; Chol, cholestatic; TB, total bilirubin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ULN, upper limit of normal. Severity index, Mild, elevated ALT/ALP meeting DILI criteria with total bilirubin \< 2 mg/dL; Moderate, elevated ALT/ALP with total bilirubin ≥ 2 g/dL; Severe, elevated ALT/ALP and one of the following, ascites, encephalopathy, international normalization ratio \>1,5 and/or other organ failure considered to be due to DILI; Fatal, death or transplantation due to DILI*.

Description Of Laboratory Investigations And Diagnostic Tests {#s3}
=============================================================

To achieve complete gene capture, we sequenced all exons, intron-exon boundaries as well as the 5′ and 3′ flanking regions for both genes. Referred to the GRCh37 assembly of the human genome, the sequences studied were the following: *PTGS1*: Chromosome 9:125.131.159 to 125.158.017; *PTGS2*: Chromosome 1:186.640.825 to 186.651.605. Partially overlapping amplicons with a size lower than 400 bp were designed. A total of 62 CS1/CS2 tagged primer pairs were synthesized and used to amplify 113 DNA samples using the Access Array platform (Fluidigm). During amplification, samples were labeled with standard MID barcodes designed for the FLX454 sequencing system. After amplification and MID-labeling, individual amplicon libraries were analyzed using a Bioanalyzer 2100 (Agilent) and bioanalyzer traces were used to estimate the amplicon concentration for each sample. Samples were then pooled, and libraries were purified by SPRI using Ampure beads to remove all possible traces of small molecules, primers, primer-dimers, or any other contaminants. The pooled library was again quantified and titrated so that a final amount of 1.95E+10 molecules with an enrichment percentage of 7% was loaded on a Pico Titer Plate (Roche) for a 200-cycle titanium-based sequencing run, made on FLX-454 equipment. Reads were processed using an amplicon processing pipeline and sff files were used for further analyses. Coverage averaged around 50x for the whole project. Coverage for the SNPs identified (shown in [Supplemental Table 1](#SM1){ref-type="supplementary-material"}) was always over 50x. Sequencing reads were de-multiplexed and aligned using the Amplicon Variant Analyzer software v2.8 (Roche) so that reads for each particular sample- target region combination were analyzed in search of variants. Details of the amplification and sequencing primers are available in [Supplemental Table 1](#SM1){ref-type="supplementary-material"}.

The putative effect on the non-synonymous variants identified *in silico* was assessed by using the Sorting Tolerant form Intolerant (SIFT) and Polymorphism Phenotyping (PolyPhen) scores as shown in the 1,000 genomes website for every SNP, as well as the online application MutationAssessor (<http://mutationassessor.org/r3/>).

Results {#s4}
=======

The sequencing results (summarized in [Table 2](#T2){ref-type="table"}) reveal that *PTGS* genes are well conserved. Although dozens of *PTGS1* and *PTGS2* single nucleotide polymorphisms (SNPs) have been described to occur in Caucasian populations (see Agúndez et al., [@B2]), our findings show that most of these SNPs were not identified, or were extremely rare, in this cohort. Interestingly, most of the *PTGS1* and *PTGS2* SNPs included in the Illumina human exome chip or human core exome chip (Urban et al., [@B17]) are also absent in this study group. This raises doubts about the coverage of exome chips to identify genetic associations related to *PTGS1* and *PTGS2* genes.

###### 

*PTGS1* and *PTGS2* variant sequences identified in the study group.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Coordinate GRCh37.p13 (GCA_000001405.14)**   **rs ID**     **N^**°**^ case**   **1**   **2**   **3**   **4**   **5**   **6**   **7**   **8**   **9**   **10**   **11**   **12**   **13**   **Effect**                            **MAF DILI**   **MAF control**   **MAF IBS**   **MAF AFR**   **MAF AMR**   **MAF**\   **MAF EUR**   **MAF SAS**
                                                                                                                                                                                                                                                                                                                **EAS**                  
  ---------------------------------------------- ------------- ------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------- -------- -------- -------- ------------------------------------- -------------- ----------------- ------------- ------------- ------------- ---------- ------------- -------------
  **PTGS1 (COX-1)**                                                                                                                                                                                                                                                                                                                      

  9:125131480                                    rs10306108                        0       0       0       0       0       0       1       0       1       0        0        0        0        UGV                                   0.077          0.055             0.06          0.13          0.03          0.00       0.07          0.01

  9:125131631                                    rs10306109                        0       0       0       0       0       0       1       0       1       0        0        0        0        UGV                                   0.077          0.055             0.06          0.13          0.03          0.00       0.07          0.01

  9:125131688                                    rs1330344                         0       0       0       0       0       1       1       0       1       0        1        0        0        UGV                                   0.154          0.210             0.24          0.52          0.21          0.42       0.20          0.39

  9:125131832                                    rs10306225                        0       0       0       0       0       0       0       2       0       2        0        0        0        UGV                                   0.154          0.000             0.00          0.00          0.00          0.00       0.01          0.00

  9:125132027                                    rs115693689                       0       0       0       0       0       0       1       0       0       0        0        0        0        UGV                                   0.038          0.055             0.07          0.13          0.04          0.05       0.08          0.02

  9:125132028                                    rs114079139                       0       0       0       0       0       0       1       0       0       0        0        0        0        UGV                                   0.038          0.055             0.07          0.13          0.04          0.05       0.08          0.02

  9:125132069                                    rs77676149                        0       0       0       0       0       0       0       1       0       1        0        0        0        UGV                                   0.077          0.000             0.00          0.01          0.01          0.00       0.00          0.00

  9:125132223                                    rs75993350                        0       0       0       0       0       0       0       0       1       0        0        0        0        UGV                                   0.038          0.055             0.06          0.13          0.03          0.00       0.07          0.01

  9:125132311                                    rs10306110                        0       0       0       0       0       0       0       0       1       0        0        0        0        UGV                                   0.038          0.055             0.06          0.13          0.03          0.00       0.07          0.01

  9:125132522                                    rs10306114                        0       0       0       0       0       0       0       0       1       0        0        0        0        UGV                                   0.038          0.055             0.06          0.13          0.03          0.00       0.07          0.01

  9:125132909                                    rs10306115                        0       0       0       0       0       0       2       0       0       0        0        0        0        5′RRV                                 0.077          0.000             0.00          0.07          0.00          0.00       0.00          0.00

  9:125133479                                    rs1236913                         0       0       1       0       0       0       0       1       0       0        0        1        0        MSV[^a^](#TN1){ref-type="table-fn"}   0.115          0.065             0.07          0.01          0.07          0.01       0.06          0.18

  9:125133507                                    rs3842787                         0       0       1       0       0       0       0       0       0       0        0        1        0        MSV[^b^](#TN2){ref-type="table-fn"}   0.077          0.060             0.06          0.15          0.03          0.00       0.07          0.01

  9:125140206                                    rs3842788                         0       0       0       0       0       0       1       0       0       0        0        0        0        SV                                    0.038          0.025             0.02          0.32          0.03          0.07       0.04          0.04

  9:125140287                                    rs3842790                         0       0       0       0       0       0       1       0       0       0        0        0        0        SV                                    0.038          0.000             0.00          0.06          0.00          0.00       0.00          0.00

  9:125140696                                    rs2282169                         0       1       0       1       0       0       2       0       0       0        1        0        0        IV                                    0.192          0.140             0.15          0.60          0.28          0.11       0.19          0.23

  9:125140823                                    rs5787                            0       0       0       0       0       0       0       0       0       2        0        0        0        MSV[^c^](#TN3){ref-type="table-fn"}   0.077          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  9:125141239                                    rs12555242                        0       0       0       0       0       0       0       0       0       0        2        0        0        IV                                    0.077          0.070             0.02          0.00          0.03          0.05       0.02          0.08

  9:125143707                                    rs3842792                         0       0       0       0       0       0       0       0       0       0        0        1        0        MSV[^d^](#TN4){ref-type="table-fn"}   0.038          0.000             0.00          0.04          0.00          0.00       0.00          0.00

  9:125143792                                    rs5788                            0       1       0       1       0       0       1       0       0       0        0        0        0        SV                                    0.115          0.110             0.11          0.69          0.24          0.04       0.14          0.10

  9:125143882                                    rs3842794                         0       0       0       0       0       0       0       1       0       1        0        0        0        IV                                    0.077          0.000             0.00          0.02          0.00          0.00       0.00          0.00

  9:125144040                                    rs3215925                         0       1       0       1       0       0       1       0       0       0        0        0        0        IV                                    0.115          0.095             0.11          0.67          0.24          0.04       0.14          0.10

  9:125145743                                    rs3842798                         0       1       0       1       0       2       0       0       0       0        2        0        0        IV                                    0.231          0.170             0.15          0.76          0.30          0.11       0.20          0.23

  9:125155408                                    rs8046                            0       0       0       0       0       0       0       0       0       0        1        0        0        3′UTRV                                0.038          0.000             0.04          0.51          0.10          0.09       0.07          0.14

  9:125155930                                    rs10306192                        0       0       0       0       0       0       0       0       0       0        2        0        0        3′UTRV                                0.077          0.000             0.04          0.01          0.05          0.09       0.06          0.13

  9:125156374                                    rs199981440                       0       0       0       0       0       0       0       1       0       0        0        1        0        3′UTRV                                0.077          0.000             --            --            --            --         --            --

  9:125157198                                    rs10306194                        0       0       1       0       1       0       2       0       0       1        2        0        0        3′UTRV                                0.269          0.175             0.20          0.02          0.11          0.04       0.15          0.14

  9:125157316                                    rs10306196                        0       0       0       0       0       0       0       0       0       0        1        0        0        3′UTRV                                0.038          0.065             0.04          0.01          0.05          0.09       0.06          0.13

  9:125157357                                    rs10306197                        0       0       0       0       0       0       1       0       0       0        0        0        1        3′UTRV                                0.077          0.000             0.00          0.02          0.00          0.00       0.00          0.00

  9:125157672                                    rs10306199                        0       0       0       0       1       1       0       0       0       0        0        0        0        3′UTRV                                0.077          0.000             0.00          0.02          0.00          0.00       0.00          0.00

  9:125157718                                    rs9233                            0       0       0       0       0       0       0       0       0       0        1        0        0        3′UTRV                                0.038          0.065             0.04          0.01          0.05          0.09       0.06          0.14

  **PTGS2 (COX-2)**                                                                                                                                                                                                                                                                                                                      

  1:186640853                                    rs4648304                         1       0       0       0       0       0       0       0       0       0        0        0        0        3′UTRV                                0.038          0.000             0.00          0.10          0.01          0.00       0.00          0.00

  1:186641058                                    rs689470                          1       0       1       0       0       0       0       0       0       0        0        0        0        3′UTRV                                0.077          0.000             0.05          0.50          0.05          0.01       0.03          0.07

  1:186641265                                    rs689468                          0       0       1       0       0       0       0       0       0       0        0        0        0        3′UTRV                                0.038          0.005             0.03          0.00          0.01          0.01       0.02          0.03

  1:186641273                                    rs689467                          0       0       0       0       0       0       0       0       0       1        0        0        0        3′UTRV                                0.038          0.025             0.07          0.00          0.03          0.00       0.05          0.03

  1:186641577                                    rs4648299                         0       0       0       0       0       0       0       1       0       0        0        0        0        3′UTRV                                0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  1:186641682                                    rs4648298                         0       0       1       0       0       0       0       0       0       0        0        0        0        3′UTRV                                0.038          0.005             0.03          0.00          0.01          0.00       0.02          0.03

  1:186642059                                    rs4648297                         0       0       0       0       0       0       0       1       0       0        0        0        0        3′UTRV                                0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  1:186642429                                    rs2206593                         0       0       0       0       0       0       0       0       1       0        0        0        0        3′UTRV                                0.038          0.050             0.06          0.00          0.05          0.00       0.09          0.06

  1:186642856                                    rs4648292                         0       0       0       0       0       0       0       1       1       0        0        0        0        3′UTRV                                0.077          0.000             0.00          0.08          0.00          0.00       0.00          0.00

  1:186642987                                    rs5276                            1       0       0       0       0       0       0       0       0       0        0        0        0        3′UTRV                                0.038          0.015             0.00          0.18          0.01          0.00       0.00          0.00

  1:186643058                                    rs5275                            1       0       1       0       0       1       1       1       0       0        0        1        1        3′UTRV                                0.269          0.205             0.33          0.64          0.37          0.20       0.31          0.40

  1:186643204                                    rs36233646                        1       0       0       0       0       0       0       1       0       0        0        0        0        3′UTRV                                0.077          0.000             0.02          0.47          0.04          0.00       0.01          0.04

  1:186643238                                    rs4648290                         0       0       0       0       0       0       0       0       1       0        0        0        0        3′UTRV                                0.038          0.010             0.00          0.00          0.01          0.00       0.01          0.00

  1:186643803                                    rs4648288                         0       0       0       0       0       0       0       0       0       0        0        1        0        SV                                    0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  1:186645078                                    rs5279                            0       0       0       0       0       0       0       0       1       0        0        0        0        SV                                    0.038          0.005             0.00          0.08          0.00          0.00       0.00          0.00

  1:186645669                                    rs5278                            0       0       0       0       0       0       0       0       1       0        0        0        0        SV                                    0.038          0.000             0.00          0.08          0.00          0.00       0.00          0.00

  1:186645927                                    rs2066826                         0       0       0       0       0       0       0       0       1       0        0        0        0        IV                                    0.038          0.105             0.12          0.36          0.19          0.04       0.12          0.16

  1:186646005                                    rs3218622                         0       0       0       0       0       0       0       0       1       0        0        0        0        MSV[^e^](#TN5){ref-type="table-fn"}   0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  1:186647418                                    rs4648265                         0       0       0       0       0       0       0       0       0       0        1        0        0        SV                                    0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  1:186648157                                    rs2066823                         0       0       0       0       0       0       0       0       0       1        0        0        0        IV                                    0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.00

  1:186648197                                    rs5277                            0       1       1       0       0       0       0       2       0       0        2        2        1        IV                                    0.346          0.180             0.15          0.01          0.11          0.04       0.18          0.06

  1:186650163                                    rs20419                           1       0       0       0       0       0       0       0       0       0        0        0        0        RRV                                   0.038          0.000             0.00          0.10          0.01          0.00       0.00          0.00

  1:186650214                                    rs148416467                       0       0       0       0       0       0       0       2       0       0        0        0        0        RRV                                   0.077          0.000             0.15          0.08          0.00          0.00       0.00          0.00

  1:186650321                                    rs20417                           0       0       1       0       0       0       0       0       0       2        0        0        1        RRV                                   0.154          0.190             0.00          0.35          0.21          0.04       0.15          0.19

  1:186650688                                    rs20415                           1       0       0       0       0       0       0       0       0       0        0        0        0        RRV                                   0.038          0.000             0.15          0.10          0.01          0.00       0.00          0.00

  1:186650751                                    rs689466                          1       0       0       1       0       0       0       0       0       0        0        0        0        RRV                                   0.077          0.215             0.15          0.08          0.26          0.48       0.19          0.13

  1:186650846                                    rs689465                          0       0       0       0       0       0       0       0       0       2        0        0        2        RRV                                   0.154          0.235             0.11          0.16          0.18          0.05       0.13          0.16

  1:186650857                                    rs4648253                         0       1       0       0       0       0       0       0       0       0        0        0        0        RRV                                   0.038          0.000             0.00          0.00          0.00          0.00       0.00          0.01

  1:186650877                                    rs72366725                        0       0       1       0       0       0       0       0       0       0        0        0        0        RRV                                   0.038          0.005             0.05          0.27          0.04          0.00       0.03          0.03

  1:186651296                                    rs4648250                         0       0       0       0       0       0       0       0       0       2        0        0        0        RRV                                   0.077          0.015             0.00          0.00          0.07          0.03       0.01          0.07

  1:186651571                                    unknown                           0       1       0       0       0       0       0       0       0       0        0        0        0        RRV                                   0.038          0.000             --            --            --            --         --            --
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MAF, Minor allele frequency referred to the GRCh37 assembly as shown in the 1,000 genomes website <http://phase3browser.1000genomes.org/Homo_sapiens/Info/Index>. 0, Non-mutated; 1, heterozygous; 2, Homozygous for the minor allele; UGV, Upstream gene variant; RRV, Regulatory region variant.; MSV, Missense variant; SV, Synonymous variant; IV, INtron variant; UTRV, Untranslated region variant; Populations, IBS correspond to the Iberian Populations in Spain (a subpopulation of Europeans); AFR, Africans; AMR, Ad mixed americans; EAS, East asians; EUR, Europeans; SAS, South asians, as described in detail in the website <http://phase3browser.1000genomes.org/Help/Faq?id=328>. Predicted consequences for missense variants:

*Nonsynonymous (W8R), SIFT score = 0.85 (tolerated, low confidence), PolyPhen score = 0 (unknown), Mutation Assessor = neutral*.

*Nonsynonymous (P17L), SIFT score = 1.00 (tolerated, low confidence), PolyPhen score = 0 (unknown), Mutation Assessor = low impact*.

*Nonsynonymous (R108Q), SIFT score = 0.12 (tolerated), PolyPhen score = 0.21 (benign), Mutation Assessor = medium impact*.

*Nonsynonymous (K185T), SIFT score = 0.36 (tolerated), PolyPhen score = 0.007 (benign), Mutation Assessor = neutral*.

*Nonsynonymous (R228H), SIFT score = 1.00 (tolerated), PolyPhen score = 0.002 (benign), Mutation Assessor = neutral*.

In the whole population study, we identified 31 single nucleotide polymorphisms (SNPs) for *PTGS1*, including four non-synonymous SNPs. For *PTGS2* we identified 31 SNPs including one non-synonymous. We observed an increased frequency of *PTGS1* and *PTGS2* mutations among DILI patients, as compared to that observed in control individuals. Most of the SNPs identified in patients were rare among control individuals and were rare also according to the 1,000 genomes database (as shown in [Table 2](#T2){ref-type="table"}). All patients but one (case 1 in [Table 2](#T2){ref-type="table"}) had mutations at the *PTGS1* gene and all patients but one (case 5 in [Table 2](#T2){ref-type="table"}) had mutations at the *PTGS2* gene. [Table 3](#T3){ref-type="table"} summarizes the comparison of relevant SNPs across patients with late-onset DILI, the rest of DILI patients and control individuals.

###### 

Detailed genotype distribution for relevant SNPs.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Coordinate GRCh37.p13 (GCA_000001405.14)**   **rs ID**    **Effect**   **Patients with late-onset DILI**\                   **Rest of DILI patients**\                           **Control individuals**\
                                                                           ***N* = 5**\                                         ***N* = 8**\                                         ***N* = 100**\
                                                                           **(Non carriers / heterozygous/ homozygous); MAF**   **(Non carriers / heterozygous/ homozygous); MAF**   **(Non carriers / heterozygous/ homozygous); MAF**
  ---------------------------------------------- ------------ ------------ ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  9:125131832                                    rs10306225   UGV          3/0/2; 0.400                                         8/0/0; 0.000                                         100/0/0; 0.000

  9:125133479                                    rs1236913    MSV          2/3/0; 0.300                                         8/0/0; 0.000                                         88/11/1; 0.065

  9:125133507                                    rs3842787    MSV          3/2/0; 0.200                                         8/0/0; 0.000                                         89/10/1; 0.060

  9:125140823                                    rs5787       MSV          4/0/1; 0.200                                         8/0/0; 0.000                                         100/0/0; 0.000

  9:125143707                                    rs3842792    MSV          4/1/0; 0.100                                         8/0/0; 0.000                                         100/0/0; 0.000

  1:186646005                                    rs3218622    MSV          4/1/0; 0.100                                         8/0/0; 0.000                                         100/0/0; 0.000
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*MAF, Minor allele frequency; UGV, Upstream gene variant; MSV, Missense variant*.

Discussion of the Underlying Pathophysiology and the Novelty or Significance of the Case {#s5}
========================================================================================

The most remarkable findings in this study are the presence among DILI patients of SNPs causing alterations in transcription factor binding sites such as the *PTGS1* SNP rs10306225 (Agundez et al., [@B3]), and the *PTGS2* SNPs rs4648253, rs689466, and rs20417, as well as non-synonymous SNPs such as *PTGS1* rs1236913 (W 8 R), rs3842787 (P 17 L), rs5787 (R 108 Q), rs3842792 (K 185 T), and *PTGS2* rs3218622 (R 228 H). These missense variants are extremely rare among European individuals (Agúndez et al., [@B2]). The putative effects of the most relevant SNPs shown in [Table 3](#T3){ref-type="table"} have been revised elsewhere (Agúndez et al., [@B2]). In brief, besides the rs10306225 SNP, which is a promoter variant that causes a modification in a CDX1 binding site (Agundez et al., [@B3]), the rest of SNPs are non-synonymous. According to functional predictions and functional analyses (reviewed in Agúndez et al., [@B2]) the SNPs rs1236913, rs3842787 have a little functional effect, although clinical associations for these SNPs with urticaria induced by NSAIDs (Cornejo-Garcia et al., [@B7]) and myocardial infarction/stroke (Lee et al., [@B11]; Lemaitre et al., [@B12]; Gao et al., [@B8]), respectively, have been proposed. The functional effect of the rs5787 SNP is unknown, although functional prediction suggests a mild functional impact (see [Table 2](#T2){ref-type="table"}), rs3842792 SNP is predicted as functional ([Table 2](#T2){ref-type="table"}), but *in vitro* findings suggest reduced functionality (Lee et al., [@B10]), and no functional impact for the *PTGS2* SNP rs3218622 has been described.

No particular association of missense SNPs with culprit drug, age, gender, clinical presentation, type of liver injury, and severity of the disease was identified. However, as shown in [Table 1](#T1){ref-type="table"}, there is heterogeneity in the duration of treatment before DILI onset. This heterogeneity, rather than being a weakness, is a strong point in this study because it allowed discriminating the frequencies of PTGS gene variations in DILI patients with late and short-term onset. All the five DILI patients with the longest times to DILI onset (50 or more days; patients n° 3, 8, 9, 10, 12 in [Table 1](#T1){ref-type="table"}) had missense variants, and no patient with shorter time to DILI onset had such missense variants. The intergroup comparison values for carriers of any non-synonymous *PTGS* variants were as follows: Patients with late DILI onset (50 or more days) vs. the rest of DILI patients (*P* \< 0.001). Patients with late DILI onset vs. control individuals (*P* \< 0.001). By turn, no significant differences for carriers of non-synonymous *PTGS* variants were observed among patients with DILI onset shorter than 50 days and control subjects (*P* = 0.325). Haplotype analyses ([Table 4](#T4){ref-type="table"}), and linkage disequilibrium (LD) analyses ([Supplemental Table 2](#SM1){ref-type="supplementary-material"}), show that the risk is due to the presence of rare haplotypes (containing missense variants) in the group of patients with late-onset DILI, but it is not due to LD variations for these variants. The strong association observed in this report, although it is based in five cases only, suggests a relationship of non-synonymous *PTGS* gene variations with DILI onset after long-term NSAID therapy. This is a novel observation that has not been raised by previous studies. Although the putative role of *PTGS* gene variations has been explored using the Illumina human exome chip or human core exome chip, it is of note that chip coverage was very limited for *PTGS* genes (Urban et al., [@B17]). By turn, this study has complete coverage thus allowing the identification of, as yet, disregarded SNPs. Another relevant difference with most DILI genetic studies is that in this report we stratified patients according to the time to onset. It cannot be ruled out heterogeneity in the etiopathogenesis of DILI, and it is conceivable that the mechanisms involved in DILI with a late onset might be different from those involved in immediate or short-latency reactions. This study, albeit with the inherent limitations of statistical power that case reports have, reinforces the view that a complete gene coverage and a detailed phenotype stratification of DILI patients could be essential to gain strength in further genetic association studies.

###### 

Haplotype analysis.

  **Haplotype frequencies**                        **rs10306225**   **rs1236913**   **rs3842787**   **rs5787**   **rs3842792**   **rs3218622**   **Frequency (Total)**   **Frequency (late-onset DILI cases)**   **Frequency (controls)**
  ------------------------------------------------ ---------------- --------------- --------------- ------------ --------------- --------------- ----------------------- --------------------------------------- --------------------------
  1                                                A                T               C               G            A               C               0.9048                  0.300                                   0.935
  2                                                A                C               T               G            A               C               0.0619                  0.100                                   0.060
  3                                                T                T               C               A            A               C               0.0095                  0.200                                   NA
  4                                                A                C               C               G            A               C               0.0048                  NA                                      0.005
  5                                                A                T               C               G            A               T               0.0048                  0.100                                   NA
  6                                                T                C               C               G            A               C               0.0048                  0.100                                   NA
  7                                                T                T               C               G            A               C               0.0048                  0.100                                   NA
  8                                                T                T               C               G            A               C               0.0048                  0.100                                   NA
  9                                                T                T               C               G            A               C               0.0048                  0.100                                   NA
  **Haplotype association with late-onset DILI**   **rs10306225**   **rs1236913**   **rs3842787**   **rs5787**   **rs3842792**   **rs3218622**   **Frequency (Total)**   **OR (95% CI)**                         ***P*****-value**
  1                                                A                T               C               G            A               C               0.9048                  1.00                                    ---
  2                                                A                C               T               G            A               C               0.0619                  0.09 (0.01--1.43)                       0.0910
  Rare haplotypes                                  \*               \*              \*              \*           \*              \*              0.0333                  0.00 (0.00--0.09)                       0.0024

*Global haplotype association p \< 0.0001*.

*NA, not applicable; \*any nucleotide*.
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COX

:   Cyclooxygenase, prostaglandin-endoperoxide synthase

NSAID

:   Non-steroidal anti-inflammatory drug

DILI

:   Drug-induced liver injury

GWAS

:   Genome-wide association study

SNP

:   Single nucleotide polymorphism

HLA

:   Human leukocyte antigen

PTGS1

:   Prostaglandin-Endoperoxide Synthase 1

PTGS2

:   Prostaglandin-Endoperoxide Synthase 2.
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